adaptimmune therapeutics plc
adaptimmune therapeutics plc Company Information
Company Number
09338148
Website
www.adaptimmune.comRegistered Address
60 jubilee avenue, milton park, abingdon, oxfordshire, OX14 4RX
Industry
Research and experimental development on biotechnology
Telephone
01235430000
Next Accounts Due
June 2025
Group Structure
View All
Shareholders
national city nominees limited 100%
adaptimmune therapeutics plc Estimated Valuation
Pomanda estimates the enterprise value of ADAPTIMMUNE THERAPEUTICS PLC at £140.5m based on a Turnover of £48.4m and 2.9x industry multiple (adjusted for size and gross margin).
adaptimmune therapeutics plc Estimated Valuation
Pomanda estimates the enterprise value of ADAPTIMMUNE THERAPEUTICS PLC at £0 based on an EBITDA of £-114.6m and a 11.65x industry multiple (adjusted for size and gross margin).
adaptimmune therapeutics plc Estimated Valuation
Pomanda estimates the enterprise value of ADAPTIMMUNE THERAPEUTICS PLC at £79m based on Net Assets of £34.5m and 2.29x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Adaptimmune Therapeutics Plc Overview
Adaptimmune Therapeutics Plc is a live company located in abingdon, OX14 4RX with a Companies House number of 09338148. It operates in the research and experimental development on biotechnology sector, SIC Code 72110. Founded in December 2014, it's largest shareholder is national city nominees limited with a 100% stake. Adaptimmune Therapeutics Plc is a established, large sized company, Pomanda has estimated its turnover at £48.4m with rapid growth in recent years.
Upgrade for unlimited company reports & a free credit check
Adaptimmune Therapeutics Plc Health Check
Pomanda's financial health check has awarded Adaptimmune Therapeutics Plc a 4 rating. We use a traffic light system to show it exceeds the industry average on 6 measures and has 4 areas for improvement. Company Health Check FAQs
6 Strong
1 Regular
4 Weak
Size
annual sales of £48.4m, make it larger than the average company (£4.2m)
£48.4m - Adaptimmune Therapeutics Plc
£4.2m - Industry AVG
Growth
3 year (CAGR) sales growth of 148%, show it is growing at a faster rate (14.3%)
148% - Adaptimmune Therapeutics Plc
14.3% - Industry AVG
Production
with a gross margin of 55.3%, this company has a comparable cost of product (55.3%)
55.3% - Adaptimmune Therapeutics Plc
55.3% - Industry AVG
Profitability
an operating margin of -260% make it less profitable than the average company (-5.5%)
-260% - Adaptimmune Therapeutics Plc
-5.5% - Industry AVG
Employees
with 439 employees, this is above the industry average (53)
439 - Adaptimmune Therapeutics Plc
53 - Industry AVG
Pay Structure
on an average salary of £163.1k, the company has a higher pay structure (£82.9k)
£163.1k - Adaptimmune Therapeutics Plc
£82.9k - Industry AVG
Efficiency
resulting in sales per employee of £110.2k, this is less efficient (£132.1k)
£110.2k - Adaptimmune Therapeutics Plc
£132.1k - Industry AVG
Debtor Days
it gets paid by customers after 4 days, this is earlier than average (53 days)
4 days - Adaptimmune Therapeutics Plc
53 days - Industry AVG
Creditor Days
its suppliers are paid after 110 days, this is slower than average (62 days)
110 days - Adaptimmune Therapeutics Plc
62 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Adaptimmune Therapeutics Plc
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 102 weeks, this is more cash available to meet short term requirements (32 weeks)
102 weeks - Adaptimmune Therapeutics Plc
32 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 85%, this is a higher level of debt than the average (52.7%)
85% - Adaptimmune Therapeutics Plc
52.7% - Industry AVG
ADAPTIMMUNE THERAPEUTICS PLC financials
Adaptimmune Therapeutics Plc's latest turnover from December 2023 is £48.4 million and the company has net assets of £34.5 million. According to their latest financial statements, Adaptimmune Therapeutics Plc has 439 employees and maintains cash reserves of £115.6 million as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Jun 2015 | Jun 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 48,391,266 | 21,793,369 | 4,938,956 | 3,173,763 | 793,157 | 48,496,333 | 28,993,026 | 10,695,292 | 8,403,000 | 6,818,000 | 355,000 |
| Other Income Or Grants | |||||||||||
| Cost Of Sales | |||||||||||
| Gross Profit | |||||||||||
| Admin Expenses | |||||||||||
| Operating Profit | -125,795,938 | -162,336,839 | -149,379,116 | -122,145,778 | -105,329,422 | -83,597,392 | -66,821,979 | -57,401,130 | -26,472,000 | -14,670,000 | -8,438,000 |
| Interest Payable | 1,700,249 | 1,322,148 | 1,800,000 | 1,346,323 | 2,049,343 | 198,859 | 405,395 | 0 | 0 | 0 | 4,000 |
| Interest Receivable | 4,787,669 | 3,194,990 | 879,518 | 2,967,685 | 2,100,947 | 2,321,923 | 5,573,607 | 836,158 | 489,000 | 322,000 | 2,000 |
| Pre-Tax Profit | -105,008,429 | -160,463,996 | -150,299,598 | -120,524,417 | -105,277,817 | -87,788,916 | -61,653,767 | -55,575,141 | -13,031,000 | -15,068,000 | -8,440,000 |
| Tax | 11,018,704 | 21,849,562 | 26,592,771 | 15,286,665 | 12,965,503 | 13,171,964 | 7,007,434 | 3,749,153 | 1,883,000 | 1,339,000 | 982,000 |
| Profit After Tax | -93,989,725 | -138,614,434 | -123,706,827 | -105,237,752 | -92,312,314 | -74,616,952 | -54,646,333 | -51,825,989 | -11,148,000 | -13,729,000 | -7,458,000 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Retained Profit | -93,989,725 | -138,614,434 | -123,706,827 | -105,237,752 | -92,312,314 | -74,616,952 | -54,646,333 | -51,825,989 | -11,148,000 | -13,729,000 | -7,458,000 |
| Employee Costs | 71,588,665 | 74,305,210 | 69,184,739 | 54,111,138 | 40,182,384 | 52,384,678 | 36,292,436 | 29,011,676 | 15,105,000 | 8,362,000 | 2,133,000 |
| Number Of Employees | 439 | 534 | 463 | 394 | 410 | 409 | 330 | 266 | 173 | 79 | 31 |
| EBITDA* | -114,607,049 | -148,724,412 | -141,669,077 | -113,755,113 | -99,667,044 | -77,232,274 | -62,843,130 | -54,970,999 | -25,227,000 | -14,204,000 | -8,290,000 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Jun 2015 | Jun 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 43,326,644 | 45,425,865 | 43,027,309 | 40,134,713 | 41,121,872 | 35,996,740 | 38,031,267 | 25,985,687 | 22,469,000 | 3,429,000 | 840,000 |
| Intangible Assets | 19,499,077 | 17,774,745 | 10,780,723 | 11,032,796 | 9,460,625 | 6,264,059 | 5,673,998 | 4,439,171 | 2,769,000 | 113,000 | 0 |
| Investments & Other | 2,429,156 | 2,465,280 | 0 | 0 | 0 | 3,339,038 | 3,259,253 | 3,025,988 | 4,508,000 | 0 | 0 |
| Debtors (Due After 1 year) | 0 | 0 | 1,780,722 | 3,690,161 | 4,947,688 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Fixed Assets | 62,825,720 | 63,200,610 | 53,808,032 | 51,167,508 | 50,582,496 | 42,260,798 | 43,705,264 | 30,424,858 | 25,238,000 | 3,542,000 | 840,000 |
| Stock & work in progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Debtors | 659,067 | 5,968,532 | 604,016 | 111,459 | 0 | 156,479 | 157,867 | 1,114,878 | 4,450,000 | 2,000 | 16,000 |
| Group Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Misc Debtors | 0 | 0 | 13,755,020 | 0 | 0 | 0 | 9,063,529 | 5,269,303 | 8,793,000 | 4,247,000 | 1,636,000 |
| Cash | 115,590,431 | 86,724,733 | 120,440,160 | 45,611,418 | 35,636,929 | 55,728,606 | 64,405,701 | 136,702,824 | 194,263,000 | 145,666,000 | 30,105,000 |
| misc current assets | 13,687,084 | 88,774,183 | 176,411,245 | 257,033,117 | 35,906,970 | 132,456,398 | 102,771,860 | 6,631,262 | 59,238,000 | 37,753,000 | 0 |
| total current assets | 166,941,479 | 205,680,340 | 335,927,711 | 319,262,289 | 85,176,021 | 188,341,483 | 176,398,958 | 149,718,267 | 266,744,000 | 187,668,000 | 31,757,000 |
| total assets | 229,767,199 | 268,880,950 | 389,735,743 | 370,429,797 | 135,758,517 | 230,602,281 | 220,104,222 | 180,143,125 | 291,982,000 | 191,210,000 | 32,597,000 |
| Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 6,561,772 | 3,843,622 | 6,600,000 | 5,153,556 | 4,534,144 | 3,584,352 | 6,420,415 | 8,812,053 | 7,883,000 | 1,259,000 | 594,000 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 4,330,095 | 2,250,140 | 2,117,269 | 2,223,558 | 1,762,335 | 0 | 0 | 0 | 0 | 0 | 0 |
| other current liabilities | 47,547,560 | 46,505,577 | 41,771,083 | 23,953,170 | 17,979,640 | 16,330,887 | 50,529,542 | 21,523,163 | 20,006,000 | 15,758,000 | 30,588,000 |
| total current liabilities | 58,439,432 | 52,599,342 | 50,488,353 | 31,330,286 | 24,276,120 | 19,915,240 | 56,949,958 | 30,335,217 | 27,889,000 | 17,017,000 | 31,182,000 |
| loans | 32,002,888 | 33,022,396 | 39,230,522 | 33,578,702 | 32,469,956 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 16,001,444 | 16,511,198 | 19,615,261 | 16,789,351 | 16,234,978 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 119,659,629 | 129,157,903 | 142,347,791 | 39,499,639 | 0 | 4,412,387 | 2,949,651 | 21,169,868 | 26,645,000 | 9,100,000 | 0 |
| other liabilities | 1,127,077 | 1,040,378 | 540,562 | 516,398 | 422,734 | 0 | 0 | 0 | 0 | 0 | 0 |
| provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total long term liabilities | 136,788,151 | 146,709,480 | 162,503,614 | 56,805,388 | 16,657,712 | 4,412,387 | 2,949,651 | 21,169,868 | 26,645,000 | 9,100,000 | 0 |
| total liabilities | 195,227,583 | 199,308,822 | 212,991,967 | 88,135,674 | 40,933,832 | 24,327,627 | 59,899,609 | 51,505,085 | 54,534,000 | 26,117,000 | 31,182,000 |
| net assets | 34,539,616 | 69,572,129 | 176,743,775 | 282,294,122 | 94,824,685 | 206,274,654 | 160,204,613 | 128,638,041 | 237,448,000 | 165,093,000 | 1,415,000 |
| total shareholders funds | 34,539,616 | 69,572,128 | 176,743,775 | 282,294,122 | 94,824,685 | 206,274,654 | 160,204,613 | 128,638,041 | 237,448,000 | 165,093,000 | 1,415,000 |
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Jun 2015 | Jun 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||
| Operating Profit | -125,795,938 | -162,336,839 | -149,379,116 | -122,145,778 | -105,329,422 | -83,597,392 | -66,821,979 | -57,401,130 | -26,472,000 | -14,670,000 | -8,438,000 |
| Depreciation | 7,588,504 | 4,239,383 | 6,957,430 | 7,615,267 | 5,069,984 | 5,858,191 | 3,856,234 | 2,354,802 | 1,176,000 | 447,000 | 148,000 |
| Amortisation | 3,600,385 | 9,373,043 | 752,610 | 775,398 | 592,393 | 506,927 | 122,614 | 75,329 | 69,000 | 19,000 | 0 |
| Tax | 11,018,704 | 21,849,562 | 26,592,771 | 15,286,665 | 12,965,503 | 13,171,964 | 7,007,434 | 3,749,153 | 1,883,000 | 1,339,000 | 982,000 |
| Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors | -5,309,464 | -10,171,227 | 12,338,139 | -1,146,069 | 4,791,209 | -9,064,917 | 2,837,216 | -6,858,820 | 11,591,000 | 2,597,000 | 1,652,000 |
| Creditors | 2,718,150 | -2,756,378 | 1,446,444 | 619,412 | 949,792 | -2,836,063 | -2,391,637 | 929,053 | 7,289,000 | 665,000 | 594,000 |
| Accruals and Deferred Income | -8,456,291 | -8,455,394 | 120,666,065 | 45,473,169 | -2,763,634 | -32,735,919 | 10,786,162 | -3,957,969 | 16,063,000 | -5,730,000 | 30,588,000 |
| Deferred Taxes & Provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash flow from operations | -104,017,022 | -127,915,396 | -5,301,935 | -51,229,798 | -93,306,593 | -90,567,375 | -50,278,388 | -47,391,942 | -11,583,000 | -20,527,000 | 22,222,000 |
| Investing Activities | |||||||||||
| capital expenditure | |||||||||||
| Change in Investments | -36,124 | 2,465,280 | 0 | 0 | -3,339,038 | 79,785 | 233,265 | -1,482,012 | 4,508,000 | 0 | 0 |
| cash flow from investments | |||||||||||
| Financing Activities | |||||||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long term loans | -1,019,508 | -6,208,126 | 5,651,820 | 1,108,746 | 32,469,956 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hire Purchase and Lease Commitments | 1,570,201 | -2,971,192 | 2,719,621 | 1,015,596 | 17,997,313 | 0 | 0 | 0 | 0 | 0 | 0 |
| other long term liabilities | 86,699 | 499,816 | 24,164 | 93,664 | 422,734 | 0 | 0 | 0 | 0 | 0 | 0 |
| share issue | |||||||||||
| interest | 3,087,420 | 1,872,842 | -920,482 | 1,621,362 | 51,604 | 2,123,064 | 5,168,212 | 836,158 | 489,000 | 322,000 | -2,000 |
| cash flow from financing | 62,682,025 | 24,636,127 | 25,631,603 | 296,546,557 | 31,803,953 | 122,810,056 | 91,381,117 | -56,147,812 | 247,670,000 | 177,729,000 | 8,871,000 |
| cash and cash equivalents | |||||||||||
| cash | 28,865,698 | -33,715,427 | 74,828,742 | 9,974,489 | -20,091,677 | -8,677,095 | -72,297,123 | -57,560,176 | 164,158,000 | 115,561,000 | 30,105,000 |
| overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| change in cash | 28,865,698 | -33,715,427 | 74,828,742 | 9,974,489 | -20,091,677 | -8,677,095 | -72,297,123 | -57,560,176 | 164,158,000 | 115,561,000 | 30,105,000 |
adaptimmune therapeutics plc Credit Report and Business Information
Adaptimmune Therapeutics Plc Competitor Analysis
Perform a competitor analysis for adaptimmune therapeutics plc by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other large companies, companies in OX14 area or any other competitors across 12 key performance metrics.
adaptimmune therapeutics plc Ownership
ADAPTIMMUNE THERAPEUTICS PLC group structure
Adaptimmune Therapeutics Plc has 1 subsidiary company.
Ultimate parent company
ADAPTIMMUNE THERAPEUTICS PLC
09338148
1 subsidiary
adaptimmune therapeutics plc directors
Adaptimmune Therapeutics Plc currently has 9 directors. The longest serving directors include Mr David Mott (Feb 2015) and Dr Ali Behbahani (Feb 2015).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr David Mott | England | 59 years | Feb 2015 | - | Director |
| Dr Ali Behbahani | England | 47 years | Feb 2015 | - | Director |
| Mr Lawrence Alleva | England | 75 years | Mar 2015 | - | Director |
| Mr John Furey | England | 60 years | Jul 2018 | - | Director |
| Mr Adrian Rawcliffe | England | 52 years | Sep 2019 | - | Director |
| Dr Andrew Allen | England | 58 years | Jun 2023 | - | Director |
| Mr Garry Menzel | United States | 60 years | Jun 2023 | - | Director |
| Dr Priti Hegde | England | 52 years | Jun 2023 | - | Director |
| Dr Kristen Hege | England | 61 years | Nov 2023 | - | Director |
P&L
December 2023turnover
48.4m
+122%
operating profit
-125.8m
-23%
gross margin
55.4%
+2.11%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2023net assets
34.5m
-0.5%
total assets
229.8m
-0.15%
cash
115.6m
+0.33%
net assets
Total assets minus all liabilities
adaptimmune therapeutics plc company details
company number
09338148
Type
Public limited with Share Capital
industry
72110 - Research and experimental development on biotechnology
incorporation date
December 2014
age
10
incorporated
UK
ultimate parent company
accounts
Group
last accounts submitted
December 2023
previous names
adaptimmune therapeutics limited (April 2015)
accountant
-
auditor
KPMG LLP
address
60 jubilee avenue, milton park, abingdon, oxfordshire, OX14 4RX
Bank
-
Legal Advisor
-
adaptimmune therapeutics plc Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 2 charges/mortgages relating to adaptimmune therapeutics plc. Currently there are 2 open charges and 0 have been satisfied in the past.
adaptimmune therapeutics plc Companies House Filings - See Documents
| date | description | view/download |
|---|
